Menu Search
Equities

Integragen SA

7N8:STU

Integragen SA

Actions
  • Price (EUR)0.42
  • Today's Change-0.01 / -2.33%
  • Shares traded0.00
  • 1 Year change-54.45%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.

  • Revenue in EUR (TTM)12.54m
  • Net income in EUR-171.40k
  • Incorporated2000
  • Employees55.00
  • Location
    Integragen SAGenopole Campus 1Genavenir 8 5 rue Henri DesbrueresEVRY 91000FranceFRA
  • Phone+33 160910900
  • Fax+33 160910928
  • Websitehttps://integragen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.